<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02312076</url>
  </required_header>
  <id_info>
    <org_study_id>MSA3</org_study_id>
    <nct_id>NCT02312076</nct_id>
  </id_info>
  <brief_title>GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles</brief_title>
  <official_title>Gonadotropin Releasing Hormone Agonist for Luteal Phase Support in Long Gonadotropin Releasing Hormone Agonist Protocol Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the effect of adding a single dose of gonadotropin releasing hormone agonist
      (GnRHa) as a luteal phase support on the outcomes of intracytoplasmic sperm injection (ICSI)
      following long GnRHa protocol
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endometrial preparation for embryo transfer (ET) will be started after oocyte retrieval by
      giving 800 mg/day natural progesterone vaginal supplement + 4 mg/day estradiol oral
      supplement. The patients will be randomly divided into 2 groups for luteal phase support: (i)
      Group A (GnRHa group) in which the luteal phase support will be continued by the same regimen
      started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with
      subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after
      oocyte retrieval, and (ii) Group B (control group) in which the luteal phase support will be
      continued only by the same regimen started on the day of oocytes retrieval until 2 weeks
      after ET
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>6 weeks after embryo transfer</time_frame>
    <description>Number of clinical pregnancies (defined as presence of at least one intrauterine gestational sac with fetal pole and cardiac activity on TVS scan at 4-6 weeks after the ET) divided by the number of ET procedures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>6 weeks after embryo transfer</time_frame>
    <description>Number of gestational sacs on TVS scan at 4-6 weeks after ET divided by the number of transferred embryos</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>12 weeks gestational age</time_frame>
    <description>Number of first trimester miscarriages (before 12 weeks gestational age) divided by the number of clinical pregnancies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>GnRHa group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Luteal phase SC administration of a single dose (0.2 mg) of GnRHa (Triptorelin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No GnRHa administration in luteal phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin</intervention_name>
    <description>Luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval</description>
    <arm_group_label>GnRHa group</arm_group_label>
    <other_name>Decapeptyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women subjected to ICSI through controlled ovarian hyperstimulation (COH) with
             pituitary downregulation by GnRHa.

        Exclusion Criteria:

          -  Moderate or severe endometriosis.

          -  Hydrosalpinx.

          -  Uterine abnormalities.

          -  Myoma.

          -  Previous uterine surgery.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed S Abdelhafez, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed Badawy, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed S Abdelhafez, Dr</last_name>
    <phone>+201144523366</phone>
    <email>msabdelhafez@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fertility Care Unit (FCU) in Mansoura University Hospital</name>
      <address>
        <city>Mansourah</city>
        <state>Dakahlia</state>
        <zip>35111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed S Abdelhafez, Dr</last_name>
      <phone>+201144523366</phone>
      <email>msabdelhafez@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Private fertility care centers</name>
      <address>
        <city>Mansourah</city>
        <state>Dakahlia</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>December 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2014</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Mohamed Sayed Abdelhafez</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Luteal phase support, ICSI, GnRHa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

